Shaily Engineering Plastics has reported strong financial results for FY26, with revenue reaching Rs. 990.7 crore, a 26% increase over the previous year. Profit after tax (PAT) surged by 83% to Rs. 169.9 crore. Driven by growth in the healthcare segment, the company continues to diversify its manufacturing platform into high-growth areas like semiconductor trays and consumer electronics, backed by a board-approved fund-raising plan of up to Rs. 500 crore.
Robust Financial Growth
Shaily Engineering Plastics delivered a stellar performance in FY26. The company’s annual revenue rose to Rs. 990.7 crore, reflecting a solid 26% YoY growth. Profitability metrics showed significant improvement, with EBITDA climbing 61% to Rs. 287.7 crore and Profit After Tax (PAT) reaching Rs. 169.9 crore, a massive 83% increase over FY25. Quarterly performance for Q4 FY26 also remained positive, with revenue at Rs. 236.8 crore and a PAT of Rs. 40.2 crore.
Strategic Business Expansion
The healthcare segment remains the primary driver of growth. Key highlights include the successful commercial launch of Shaily Harmony and Shaily Neo pens for Semaglutide, and a significant Rs. 423 crore order from a large domestic pharma company for pen injectors. Beyond healthcare, the company is successfully executing its diversification strategy by entering the semiconductor supply chain, having recently signed an agreement with a Korean firm for the manufacture and supply of semiconductor trays.
Future Capital Strategy
To support its evolution into a diversified, IP-led global manufacturing platform, the Board has approved an enabling resolution to raise up to Rs. 500 crore. This funding, proposed via routes such as Qualified Institutions Placement (QIP) or rights issues, is intended to provide the company with the financial flexibility to capitalize on expanding addressable markets and growth opportunities across its existing business verticals, including industrial components and consumer electronics.
Source: BSE
